Sanofi Wins First EU Approval for Therapy Delaying Type 1 Diabetes Onset

Paris, Monday, 12 January 2026.
On January 12, 2026, Sanofi achieved a significant regulatory milestone as the European Commission approved Teizeild (teplizumab), marking the European Union’s first disease-modifying therapy authorized to delay the onset of stage 3 type 1 diabetes. This approval, applicable to adults and children aged eight and older with stage 2 diabetes, is grounded in compelling data from the TN-10 Phase 2 study. The trial demonstrated that Teizeild could delay disease progression by a median of two years, a critical timeframe for patients and families. Analytically, the results were robust: 57% of patients treated with the therapy remained in stage 2, compared to only 28% in the placebo group. This authorization not only strengthens Sanofi’s immunology portfolio but represents a paradigm shift in diabetes management, moving from reactive symptomatic treatment to proactive preventative intervention for high-risk individuals across the European market.